Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01256398 · ClinicalTrials.gov registry record · Phase 2
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT01256398: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01256398 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 66 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01256398, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
This phase II clinical trial studies how well dasatinib followed by stem cell transplant works in treating older patients with newly diagnosed acute lymphoblastic leukemia. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Monoclonal antibodies, such as alemtuzumab, may interfere with the ability of cancer cells to grow and spread. Giving more than one drug (combination chemotherapy) and giving dasatinib together with chemotherapy may kill more cancer cells.
Interventions
- DRUG Cyclophosphamide
- DRUG Cytarabine
- PROCEDURE Allogeneic Hematopoietic Stem Cell Transplantation
- PROCEDURE Autologous Hematopoietic Stem Cell Transplantation
- BIOLOGICAL Alemtuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2010-12-14 |
| Est. Completion | 2021-11-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01256398
The ClinicalTrials.gov registry entry for NCT01256398 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT01256398 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01256398 about?
NCT01256398 is a clinical study titled "Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia". This phase II clinical trial studies how well dasatinib followed by stem cell transplant works in treating older patients with newly diagnosed acute lymphoblastic leukemia. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving chemotherapy befor...
What is the current status of trial NCT01256398?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2010-12-14. Estimated completion is 2021-11-15.
What interventions are being tested in trial NCT01256398?
The interventions under investigation include: Cyclophosphamide (DRUG), Cytarabine (DRUG), Allogeneic Hematopoietic Stem Cell Transplantation (PROCEDURE), Autologous Hematopoietic Stem Cell Transplantation (PROCEDURE), Alemtuzumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01256398?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.